Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

Eli Lilly Canada, Inc announced today that Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets) is now approved and available ...

In patients experiencing refractory ischemic digital complications from systemic sclerosis or other diseases, BTX injections are safe and effective.

The FDA's breakthrough therapy designation facilitates accelerated development and regulatory review for therapies showing ...